Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Frontiers Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations

Metastatic Melanoma Therapies OPDIVO® (nivolumab) + YERVOY® (ipilimumab)

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases - Cancer Therapy Advisor

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy - Pires da Silva - 2020 - Cancer - Wiley Online Library

Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress

Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - The Lancet Oncology

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma